In today’s fast-paced, innovation-fueled biopharma landscape, the traditional model of C-suite leadership is being turned on ...

One of the goals of the current administration is to implement the use of AI in FDA’s approval process. Proponents of the ...

The Medipost CEO discusses developing treatments for knee osteoarthritis and other conditions.

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...

The National Alliance on Mental Illness (NAMI) issued a response to the bill, stating that the cuts to Medicare and Medicaid ...

The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...